<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="945">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148845</url>
  </required_header>
  <id_info>
    <org_study_id>Sisonke Boost Open Label Study</org_study_id>
    <nct_id>NCT05148845</nct_id>
  </id_info>
  <brief_title>Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.</brief_title>
  <acronym>Sisonke Boost</acronym>
  <official_title>Open-label, Single-arm Phase 3B Implementation Study to Evaluate the Effectiveness of the Homologous Boostof Ad26.COV2.S COVID-19 Vaccine Following the Prime Dose Among Sisonke Participants in South Africa(VAC31518COV30XX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wits Health Consortium (Pty) Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Department of Health of South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Communicable Diseases - NICD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hutchinson Center Research Institute of South Africa (HCRISA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bio Analytical Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dis-Chem Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioVac</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biocair</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Right to Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Laboratory Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Infectious Disease and Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wits Health Consortium (Pty) Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine plus a&#xD;
      homologous boostwith Ad26.COV2.S COVID-19 vaccine among Sisonke participants as compared to&#xD;
      unboosted Sisonkeparticipants; vaccinated; and unvaccinated populations in South Africa&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen)&#xD;
      COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among&#xD;
      Sisonke participants as compared to unboosted Sisonke participants&#xD;
&#xD;
      In addition the investigators will continue to evaluate VE of the Sisonke Boost compared to:&#xD;
&#xD;
      i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa.&#xD;
&#xD;
      Study design Open-label, single-arm phase 3B vaccine implementation study&#xD;
&#xD;
      Rationale South Africa is severely affected by the global COVID-19 epidemic, and following&#xD;
      the initial prime vaccination among HCWs in the first 4 months of 2021. New data has&#xD;
      demonstrated the safety and effectiveness of a booster dose given two months or more after&#xD;
      the initial Ad26.COV2.S. This provides the rationale and feasibility for the evaluation of a&#xD;
      homologous booster vaccine dose to the cohort of vaccinated Sisonke participants to inform&#xD;
      the larger vaccine rollout.&#xD;
&#xD;
      Study participants Sisonke participants age 18 and over working in the South African public&#xD;
      and private health care sector (approx N=500 000) who were enrolled in Sisonke and have not&#xD;
      subsequently had a further booster vaccine dose.&#xD;
&#xD;
      Study sites Department of Health Vaccine Administration Sites across South Africa supported&#xD;
      by the Sisonke (Together) (VAC31518COV3012) Trial Research Site Investigators and Study Staff&#xD;
&#xD;
      Study duration Participants will receive a homologous Ad26.COV2.S (Janssen) booster dose of&#xD;
      vaccine at least 6 months post the prime vaccination. The investigators will monitor outcomes&#xD;
      utilising the DATCOV surveillance system and NHLS/NICD SARS COV-2 testing databases for up to&#xD;
      2 years post initial vaccination.&#xD;
&#xD;
      Study products Ad26.COV2.S by Janssen administered as a single dose followed by a single&#xD;
      booster injection.&#xD;
&#xD;
      Primary objectives â€¢ To assess the effectiveness of Ad26.COV2.S vaccine as a homologous boost&#xD;
      on severe COVID, hospitalizations and deaths in Sisonke participants as compared with the&#xD;
      unboosted Sisonke populations.&#xD;
&#xD;
      Secondary objectives To assess the effectiveness of Ad26.COV2.S vaccine as a homologous boost&#xD;
      on severe COVID, hospitalizations and deaths in Sisonke participants as compared vaccinated&#xD;
      and unvaccinated populations of essential workers in South Africa.&#xD;
&#xD;
        -  To estimate the incidence of symptomatic SARS CoV-2 infections in Sisonke participants&#xD;
           following a boost compared with the unboosted Sisonke populations and general vaccinated&#xD;
           and unvaccinated population in South Africa&#xD;
&#xD;
        -  To estimate booster dose uptake among Sisonke participants in South Africa&#xD;
&#xD;
        -  To monitor the genetic diversity of breakthrough SARS CoV-2 infections.&#xD;
&#xD;
        -  To monitor safety in the case of homologous boosts in Sisonke participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single-arm phase 3B vaccine implementation study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effectiveness of Ad26.COV2.S (Janssen) boost vaccine on severe COVID, hospitalizations and deaths in Sisonke participants as compared to unboosted Sisonke participants (single Ad26 vaccine only)</measure>
    <time_frame>24 Months</time_frame>
    <description>Rates of hospitalizations and deaths among boosted Sisonke participants versus unboosted Sisonke participants and unvaccinated populations in South Africa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effectiveness of Ad26.COV2.S (Janssen) boost vaccine on severe COVID, hospitalizations and deaths in Sisonke participants as compared to the vaccinated and unvaccinated populations (no vaccination) in South Africa.</measure>
    <time_frame>24 Months</time_frame>
    <description>Rates of hospitalizations and deaths among boosted Sisonke participants versus unboosted vaccinated and unvaccinated populations in South Africa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence of symptomatic SARS CoV-2 infections among boosted Sisonke ppts.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence rate of SARS CoV-2 infection as indicated by self-report and validation in national laboratory records.&#xD;
Rates of severe disease in Sisonke participants who are found to be RT-PCR positive at any time up to 2 years post prime vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor the genetic diversity of breakthrough SARS CoV-2 infections</measure>
    <time_frame>24 Months</time_frame>
    <description>Genetic diversity of breakthrough infection virus as determined by whole genome sequencing. This will be recovered from national laboratories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate booster vaccine uptake among Sisonke participants in South Africa</measure>
    <time_frame>24 Months</time_frame>
    <description>Proportion of Sisonke participants approached for study participation taking part in the boost study and receiving the booster vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor safety in homologous boosts</measure>
    <time_frame>24 Months</time_frame>
    <description>All SAEs and events of special interest will be collected and reported.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500000</enrollment>
  <condition>SARS CoV 2 Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Booster vaccine</intervention_name>
    <description>To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants&#xD;
In addition we will continue to evaluate VE of the Sisonke Boost compared to:&#xD;
i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age 18 and older&#xD;
&#xD;
          -  All Sisonke participants&#xD;
&#xD;
          -  Received a priming Ad26.SARS.COV.2.S vaccination as part of the Sisonke study at least&#xD;
             6 months prior&#xD;
&#xD;
          -  Participants who are pregnant or report breastfeeding at the time of enrolment may be&#xD;
             included.&#xD;
&#xD;
          -  Willingness and ability to comply with vaccination plan and other study procedures.&#xD;
&#xD;
          -  Capable of giving electronic or personal signed informed consent as described in&#xD;
             Appendix 5, which includes compliance with the requirements in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have received boosting vaccination through other means.&#xD;
&#xD;
          -  Any significant acute or chronic medical condition, situation or circumstance that in&#xD;
             the opinion of the PI/designee makes the participant unsuitable for participation in&#xD;
             the study, or jeopardises the safety or rights of the participant&#xD;
&#xD;
          -  Current participation in any other research studies that would interfere with the&#xD;
             objectives of this study. The determination of whether participation in another study&#xD;
             would be exclusionary for a given participant will be made by the PI/designee.&#xD;
&#xD;
          -  Participants with a history of heparin-induced thrombocytopenia or TTS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenda Gray, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Non-Executive Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatima Mayat, BPharm</last_name>
    <phone>+2711 989 9798</phone>
    <email>mayatf@phru.co.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ravindre Panchia, MBBCh</last_name>
    <phone>+27 11 989 9700</phone>
    <email>panchiar@phru.co.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nelson Mandela Academic Clinical Research Unit (NeMACRU)</name>
      <address>
        <city>Mthatha</city>
        <state>Eastern Cape</state>
        <zip>5100</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dubula Thozama, MBBCH</last_name>
      <phone>074 502 1944</phone>
      <email>tdubula@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Thozama Dubula, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PHOENIX Pharma Pty Ltd</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel R Dr Malan, MBCHB</last_name>
      <phone>+27 41 373 3832</phone>
      <email>iel.malan@phoenixpharma.co.za</email>
    </contact>
    <investigator>
      <last_name>Daniel R Malan, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ZE E Punt, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Josha Research</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes J Lombaard, MBBCH</last_name>
      <phone>+27(0) 514 128 160</phone>
    </contact>
    <investigator>
      <last_name>Johannes j Lombaard, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Tembisa Clinical Research Centre</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng - South</state>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn T Mngadi, MBBCH</last_name>
      <phone>+27(0) 60 503 1870</phone>
      <email>kmngadi@auruminstitute.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn Mngadi, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit Kliptown</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng - South</state>
        <zip>1809</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica M Lazarus, MBBCh</last_name>
      <phone>27(0) 11 342 4075</phone>
      <email>lazaruse@phru.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Anusha Nana, BPharm</last_name>
      <phone>27(0) 11 342 4075</phone>
      <email>nanaa@phru.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Erica Lazarus, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU), SOWETO</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Lazarus, MBBCH</last_name>
      <phone>+27(0) 11 342 4075</phone>
      <email>lazaruse@phru.co.za</email>
    </contact>
    <investigator>
      <last_name>Erica Lazarus, MBCHB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit (CHRU),</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharlaa Badal-Faesan, MBBCH</last_name>
      <phone>+27(0) 11 276 8800</phone>
      <email>sfaesen@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Sharlaa Badal-faesan, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MeCRU Clinical Research Unit</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maposhane Nchabeleng, MBBCH</last_name>
      <phone>012 521 5667</phone>
      <email>maphoshane.nchabeleng@smu.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre,</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khatija K Ahmed, MBBCH</last_name>
      <phone>27(0) 12 799 2422</phone>
      <email>MMalahleha@setshaba.org.za</email>
    </contact>
    <investigator>
      <last_name>Mookho Malahleha, MBBCH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute Clinical Research Centre, Pretoria</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>2059</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coert Grobbelaar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ndlovu Research Centre</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebone Maboa, MBBCH</last_name>
      <phone>+27 13 983 8700</phone>
      <email>rmaboa@ndlovu.com</email>
    </contact>
    <investigator>
      <last_name>Maboa Rebone, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Botha's Hill Clinical Research Site</name>
      <address>
        <city>Bothas Hill</city>
        <state>KWA ZULU Natal</state>
        <zip>3660</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth e Spooner, MBCHB</last_name>
      <phone>+27(0) 31 777 1585</phone>
      <email>Elizabeth.Spooner@mrc.ac.za</email>
    </contact>
    <investigator>
      <last_name>Elizabeth E Spooner, MBCHB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAPRISA eThekwini Clinical Research Site, Dr</name>
      <address>
        <city>Durban</city>
        <state>KWA ZULU Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nivashnee Naicker</last_name>
      <phone>+27(0) 31 655 0618</phone>
      <email>Nivashnee.naicker@caprisa.org</email>
    </contact>
    <investigator>
      <last_name>Nivashnee Naicker, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chatsworth Clinical Research Site</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Logashvari Naidoo, MBBCH</last_name>
      <phone>27(0) 31 401 4150</phone>
    </contact>
    <contact_backup>
      <email>logashvari.naidoo@mrc.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Logashvari Naidoo, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAPRISA Vulindlela Clinical Research Site, Dr Disebo Makhaza</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Disebo Makhaza, MBBCH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo Research Clinic</name>
      <address>
        <city>Ladysmith</city>
        <state>KWA ZULU Natal</state>
        <zip>3370</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippus L Kotze, MBBCH</last_name>
      <phone>27(0) 36 631 2372</phone>
      <email>plkotze@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Philippus L Kotze, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongaat Clinical Research Site, Dr</name>
      <address>
        <city>Tongaat</city>
        <state>Kwa Zulu Natal</state>
        <zip>4400</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vimla Naicker, MBCHB</last_name>
      <phone>+27(0) 32 944 2208</phone>
      <email>vimla.naicker@mrc.ac.za</email>
    </contact>
    <investigator>
      <last_name>Vimla Naicker, MBCHB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mzansi Ethical Research Centre</name>
      <address>
        <city>Middleburg</city>
        <state>Mpumalanga</state>
        <zip>1050</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich Petrick, MBBCH</last_name>
      <phone>(013) 282 5218</phone>
    </contact>
    <investigator>
      <last_name>Friedrich Petrich, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute Klerksdorp Clinical Research Centre</name>
      <address>
        <city>Klerksdorp</city>
        <state>North WEST Province</state>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James C Innes, MBBCH</last_name>
      <phone>+27(0) 87 135 1616</phone>
      <email>cinnes@auruminstitute.org</email>
    </contact>
    <investigator>
      <last_name>James C Innes, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TASK Applied Science, Delft Day Hospital Premises</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7100</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Diacon, MBBCH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TASK Applied Science, Dr Ivans Toms Clinic Premises</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7100</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Diacon, MBBCH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FAMCRU (Family Clinical Research Unit),</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun L Barnabas, MBBCH</last_name>
      <phone>27(0) 21 938 4292</phone>
      <email>barnabas@sun.ac.za</email>
    </contact>
    <investigator>
      <last_name>S L Barnabas, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TASK Applied Science, Brooklyn Chest Hospital Premises</name>
      <address>
        <city>Cape town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas a Diacon, MBBCH</last_name>
      <phone>: +27(0) 21 510 2209</phone>
      <email>ahd@task.org.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TASK Central</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas a Diacon, MBChB,</last_name>
      <phone>+27(0) 21 100 3606</phone>
      <email>ahd@task.org.za</email>
    </contact>
    <investigator>
      <last_name>Andreas Diacon, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TASK Clinical Research Centre</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas A Diacon, MBBCH</last_name>
      <phone>+27 21 917 1044</phone>
      <email>ahd@task.org.za</email>
    </contact>
    <investigator>
      <last_name>Andreas A Diacon, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emavundleni Research Centre</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7781</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Mahoney</last_name>
      <phone>+27(0) 21 650 5851</phone>
      <email>lulu.nair@hiv-research.org.za</email>
    </contact>
    <investigator>
      <last_name>Scott Mahoney, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu Health Foundation CTU J52 Old Main Building Groote SchuurHospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheetal Kassim, MBCHB</last_name>
      <phone>+27(0) 21 406 6958</phone>
      <email>Sheetal.Kassim@hiv-research.org.za</email>
    </contact>
    <investigator>
      <last_name>Catherine Orrell, MBChB,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Kaplan, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>F Cilliers, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>K Middelkoop, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PK Chodacki, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Y Singh, MB ChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TASK Eden</name>
      <address>
        <city>George</city>
        <state>Western Cape</state>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Diacon, MBBCH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>South African Vaccine Initiative (SATVI)</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelique KK Luabeya</last_name>
      <phone>+27(0) 23 346 5400</phone>
      <email>Angelique.luabeya@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Angelique KK Luabeya, MBCHB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu Health Foundation - Masiphumelele Research Office</name>
      <address>
        <city>Cape Town</city>
        <zip>7975</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine M Gill, MBBCH</last_name>
      <phone>+27(0) 21 785 3121</phone>
      <email>katherine.gill@hiv-research.org.za</email>
    </contact>
    <investigator>
      <last_name>KATHERINE M Gill, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Rustenburg Clinical Research Centre, Dr Lawrence</name>
      <address>
        <city>Rustenburg</city>
        <zip>0299</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William L Brumskine, MBBCH</last_name>
      <phone>+27(0) 87 135 1575</phone>
      <email>wbrumskine@auruminstitute.org</email>
    </contact>
    <investigator>
      <last_name>William L Brumskine, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 4, 2021</last_update_submitted>
  <last_update_submitted_qc>December 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All study team scientists will disseminate the trial results as broadly as possible. Data will be shared with JNJ prior to release to the public. The study data will be published consistent with normal scientific practices.&#xD;
The results from this research may also be disseminated through presentations at scientific institutions/ meetings, and/or publication in scientific journals. All publications will be uploaded to a publication repository. After sharing the results with study participants, they will be presented to communities from which participants are recruited, following Good Participatory Practice guidelines. The results will also be shared with global and local policy makers. Summary results of the trial will be made publicly available through the clinical trial registry. Any datasets used for analysis in publications can be requested by investigators via an online request to the organisation. Measures will be taken to protect identifiable information in the datasets</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Within 12 months of completion of study</ipd_time_frame>
    <ipd_access_criteria>on request</ipd_access_criteria>
    <ipd_url>https://www.samrc.ac.za</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

